Company Sees FY26 Revenue Guidance of $4.632B to $4.72B
Sees FY26 revenue $4.632B-$4.72B, consensus $4.66B. The company's initial 2026 revenue guidance range of $4.632B-$4.72B, or reported growth of 7.6%-9.6% and 7.0%-9.0% on an organic basis, is supported by 8.6% - 10.6% reported and 8.0%-10.0% organic CAG Diagnostics recurring revenue growth. The guidance range for global CAG Diagnostics recurring revenue growth reflects expectations for sustained benefits from execution drivers, supporting continued solid volume gains, and an estimated 4% full-year benefit from net price improvement. 2026 EPS guidance of $14.29-$14.80 reflects expectations for solid organic revenue gains and a targeted 40-90 basis points of reported operating margin improvement.
